Sutent sunitinib: Phase III data

Data from the open-label Phase III SUN 1064 trial for first-line treatment of advanced HER2-negative breast

Read the full 168 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE